Colon carcinogenesis is modulated through an imbalance between apoptosis and proliferation. Both of these kinetic factors can be modulated by genetic and dietary/lumenal risk factors. Increased levels of secondary bile acids (a lumenal risk factor) result from certain types of diet (e.g. high fat, red meat) and increased fecal content of these bile acids are associated with increased risk of colon cancer. We have recently shown that endogenous levels of nitric oxide (NO) protect colonic epithelial cells from bile acid-induced apoptosis and that NOS2 levels are elevated in adenomas. We have also recently discovered an important downstream effector pathway of deoxycholate (DOC) that results in the modification of proteins by peroxynitrite (ONOO). Apoptosis resistance coupled with the deleterious effects of ONOO can contribute to mutation and enhanced tumorigenesis. Since iron (present in red meat) increases NOS2 levels, increased bile acids and iron may represent independent risk factors in colon carcinogenesis. We will explore the effects of bile acids and iron supplementation on tumor formation using normal and genetically-modified mice (e.g. NOS2 knock-out). Since DOC activates cyclooxygenase-2 (COX-2), an enzyme also elevated in colon tumors, the role that the COX-2 pathway has in the formation of ONOO-, the nitration of proteins and protection against bile acid-induced apoptosis needs to be explored. The goals of this project are, therefore, to understand the mechanism(s) by which NO affects apoptosis in colonic cells and tissues and influences colon carcinogenesis, determine if genes associated with NO metabolism mediate the effects of genetic and/or lumenal risk factors, and use this information to identify new markers of colon cancer risk in humans. To accomplish these goals we will use in vitro tissue culture models, a unique ex vivo human colonic biopsy model of apoptosis, human colon resections and genetically-modified mice in conjunction with molecular and cellular techniques.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA072008-05
Application #
6563873
Study Section
Subcommittee G - Education (NCI)
Project Start
2002-01-01
Project End
2002-12-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
5
Fiscal Year
2002
Total Cost
$130,479
Indirect Cost
Name
University of Arizona
Department
Type
DUNS #
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Raj, K P; Zell, J A; Rock, C L et al. (2013) Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas. Br J Cancer 108:512-8
Laukaitis, Christina M; Erdman, Steven H; Gerner, Eugene W (2012) Chemoprevention in patients with genetic risk of colorectal cancers. Colorectal Cancer 1:225-240
Rial, Nathaniel S; Zell, Jason A; Cohen, Alfred M et al. (2012) Clinical end points for developing pharmaceuticals to manage patients with a sporadic or genetic risk of colorectal cancer. Expert Rev Gastroenterol Hepatol 6:507-17
Laukaitis, Christina M; Gerner, Eugene W (2011) DFMO: targeted risk reduction therapy for colorectal neoplasia. Best Pract Res Clin Gastroenterol 25:495-506
Zell, Jason A; Ziogas, Argyrios; Ignatenko, Natalia et al. (2009) Associations of a polymorphism in the ornithine decarboxylase gene with colorectal cancer survival. Clin Cancer Res 15:6208-16
Feldman, Rebecca; Martinez, Jesse D (2009) Growth suppression by ursodeoxycholic acid involves caveolin-1 enhanced degradation of EGFR. Biochim Biophys Acta 1793:1387-94
Gerner, Eugene W; Meyskens Jr, Frank L (2009) Combination chemoprevention for colon cancer targeting polyamine synthesis and inflammation. Clin Cancer Res 15:758-61
Rial, Nathaniel S; Lazennec, Gwendal; Prasad, Anil R et al. (2009) Regulation of deoxycholate induction of CXCL8 by the adenomatous polyposis coli gene in colorectal cancer. Int J Cancer 124:2270-80
Zell, Jason A; Pelot, Daniel; Chen, Wen-Pin et al. (2009) Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas. Cancer Prev Res (Phila) 2:209-12
Ashbeck, Erin L; Jacobs, Elizabeth T; Martínez, María Elena et al. (2009) Components of metabolic syndrome and metachronous colorectal neoplasia. Cancer Epidemiol Biomarkers Prev 18:1134-43

Showing the most recent 10 out of 88 publications